Genxone (WAR:GX1) NonCurrent Deferred Liabilities: zł0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:GX1 Genxone SA WAR:GX1
69 GF Score
Price zł5.60
GF Value zł6.40
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genxone NonCurrent Deferred Liabilities?

Genxone WAR:GX1 +1.82% 69 NonCurrent Deferred Liabilities is zł0.00 Mil as of Mar. 2026. GuruFocus rates WAR:GX1 with a GF Score™ of 69/100 and a GF Value™ of zł6.40 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Genxone's non-current deferred liabilities for the quarter that ended in Mar. 2026 was zł0.00 Mil.

Genxone NonCurrent Deferred Liabilities Related Terms

Genxone NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Genxone's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genxone NonCurrent Deferred Liabilities Chart

Genxone Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Genxone Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WAR:GX1
69GF Score
Genxone SA WAR:GX1
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of zł0.00 Mil mean?
Genxone (WAR:GX1) has a NonCurrent Deferred Liabilities of zł0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Genxone and its competitors.
Is Genxone's NonCurrent Deferred Liabilities too high?
Genxone's current NonCurrent Deferred Liabilities is zł0.00 Mil. Overall, Genxone has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genxone's NonCurrent Deferred Liabilities compare to VRTX and REGN?
Genxone's NonCurrent Deferred Liabilities of zł0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Genxone and its competitors. Genxone's current NonCurrent Deferred Liabilities is zł0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genxone stock overvalued right now?
Based on GuruFocus' analysis, Genxone (WAR:GX1) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.40, compared to a current price of zł5.60 — trading 12.5% below its estimated fair value. The current NonCurrent Deferred Liabilities is zł0.00 Mil. Genxone's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Genxone (WAR:GX1), the current NonCurrent Deferred Liabilities is zł0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genxone (WAR:GX1) Overvalued in 2026?

Based on GuruFocus' analysis, Genxone stock appears to be undervalued. The current stock price of zł5.60 is trading 12.5% below its estimated GF Value™ of zł6.40. GuruFocus considers Genxone to be Modestly Undervalued.

Key valuation signals for WAR:GX1:

  • NonCurrent Deferred Liabilities: zł0.00 Mil
  • GF Value™: zł6.40 vs. price of zł5.60 (12.5% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the WAR:GX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genxone Business Description

Address Kobaltowa Street 6, Zlotniki, POL, 62002
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
69GF Score

Get the complete analysis for WAR:GX1

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.60
Price
zł6.40
GF Value